The Yale ADRC seeks to advance our understanding of Alzheimer's disease with the eventual goal of translating laboratory discoveries into novel effective clinical therapies. Five Cores (Administrative, Clinical, Data, Biomarker/Pathology and Outreach) and 3 Research Projects (Lysosomes, Post-Synaptic Densities and GABAergic Networks) will work together to achieve this goal. Our unifying theme is a focus on the cell biology of specific neurons, and its disruption in Alzheimer's disease triggered by abnormal forms of Amyloid-? peptide. Research Projects will focus on specific neuronal organelles and specific neuronal subtypes perturbed in disease and make use of human tissue analysis and human subject imaging to evaluate mechanistic hypotheses. The Biomarker/Pathology Core will develop novel, sensitive and high-throughput mass spectrometry assays by targeted multiple-reaction monitoring (MRM) to monitor disease mechanisms. A key emphasis will be the translational development of research findings into therapeutic benefit. To support the future strength of Alzheimer's research, the Yale ADRC will strive to advance the careers of Young Investigators through mentorship from a distinguished Internal Advisory Committee, and through Pilot Project awards. In addition to collecting clinical data and biospecimens of brain, CSF, DNA, serum, blood cells and iPSCs for analysis by members of the ADRC research team, the ADRC will support other Yale NIH-funded research studies on related topics and contribute materials to national NIA-sponsored research networks. The Outreach Core will connect with the community to provide greater knowledge regarding Alzheimer's disease and related dementia.
The Yale Alzheimer Disease Research Center (ADRC) seeks to advance our understanding of Alzheimer's disease with the eventual goal of translating laboratory discoveries into novel effective clinical therapies. Five Cores (Administrative, Clinica, Data, Biomarker/Pathology and Outreach) and 3 Research Projects (Lysosomes, Post-Synaptic Densities and GABAergic Networks) will work together to achieve this goal. Our unifying theme is a focus on the cell biology of specific neurons, and its disruption in Alzheimer's disease triggered by abnormal forms of Amyloid-? peptide.
|Meng, Jin; Ferguson, Shawn M (2018) GATOR1-dependent recruitment of FLCN-FNIP to lysosomes coordinates Rag GTPase heterodimer nucleotide status in response to amino acids. J Cell Biol 217:2765-2776|
|Nguyen, Andrew D; Nguyen, Thi A; Zhang, Jiasheng et al. (2018) Murine knockin model for progranulin-deficient frontotemporal dementia with nonsense-mediated mRNA decay. Proc Natl Acad Sci U S A 115:E2849-E2858|
|Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25|
|Scherer, Roberta W; Drye, Lea; Mintzer, Jacobo et al. (2018) The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials 19:46|
|Strittmatter, Stephen M (2018) Emerging Mechanisms in Alzheimer's Disease and Their Therapeutic Implications. Biol Psychiatry 83:298-299|
|Mecca, Adam P; Barcelos, Nicole M; Wang, Shuo et al. (2018) Cortical ?-amyloid burden, gray matter, and memory in adults at varying APOE ?4 risk for Alzheimer's disease. Neurobiol Aging 61:207-214|
|Gill, Thomas M; Han, Ling; Leo-Summers, Linda et al. (2018) Distressing Symptoms, Disability, and Hospice Services at the End of Life: Prospective Cohort Study. J Am Geriatr Soc 66:41-47|
|Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169|
|Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104|
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
Showing the most recent 10 out of 134 publications